Replies to post #196668 on Biotech Values

[jbog]

When looking at Vertex's Financials I gasp when I see their RD budget. But on the other hand they have seemed to know what they're doing, most trials are positive albeit they're taking small steps.

I think if they standalone they will be a nice long term investment. I just don't see them being independent over the long haul.

I see them as a perfect fit for Gilead.

[DewDiligence]

VRTX -2% on CRL for Kalydeco sNDA:

http://finance.yahoo.com/news/vertex-receives-complete-response-letter-130000552.html

Vertex Pharmaceuticals Incorporated today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration for its supplemental New Drug Application (sNDA) for the use of KALYDECO (ivacaftor) in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The FDA determined that it cannot approve the application in its present form. Vertex plans to meet with the FDA to determine an appropriate path forward.